Did You Know?

Editor’s Picks

Latest News

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025...

TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage

Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolioHighlightsROI model validated for savings and metrics by...

INTURAI VENTURES PROVIDES CORPORATE UPDATE

(CSE: URAI / OTC: URAIF / FSE: 3QG)                                                                                                    investor@inturai.comHighlightsU.S. OTC trading code has changed to URAIF, reflecting the Company's corporate rebrand and...

error: Content is protected !!